Where are we now? Emerging opportunities and challenges in the management of SHPT in patients with ND-CKD

Despite advances in our understanding, the optimal management of SHPT in ND-CKD remains challenging. There is a growing consensus that we must identify and treat patients with SHPT earlier in the course of the disease. However, target levels of PTH are unclear, as are the levels of vitamin D required to achieve sufficient PTH reduction. 

Based on a pivotal 2021 review by leading nephrologists Prof.  Markus Ketteler (Robert-Bosch-Krankenhaus, Stuttgart, Germany) and Prof. Patrice Ambühl (Institut für Nephrologie, Zurich, Switzerland), this infographic provides expert insights into the rationale for SHPT and elevated PTH as a therapeutic target in ND-CKD.